thought call
magnitud neg revis guidanc rev ep
surpris seem somewhat misalign call commentari still
character impact short-term disloc volum oppos
potenti long-term structur neg impact payor mix higher
uninsur rate ou price effect far clear effect
materi guidanc may overli conserv stanc
manag messag stand stark contrast lilli character
uncertainti front still view share keytruda highli
defens acknowledg near-term pressur bevi nsclc competit
risk tigit libtayo like persist next month see
path toward re-rat combin posit data rcc better
character risk pose tigit come
emerg evid manag guidanc overli conserv
could drive stock trade in-lin peer price-to-earnings ep today vs
peer lower pt reflect today updat maintain overweight
competit nsclc domin near-term narr focu tigit
ramp consider recent week expect dynam
acceler despit lack data analyz interim roch cover
emmanuel papadaki data dont think risk keytruda
nsclc domin creat equal tigit potenti far-reach
consequ shine bright light merck inabl yet defin next
transform combin keytruda extend lead less concern
disrupt commerci landscap remain tail risk
adjust estim base result commentari adjust
estim reflect larger step-down q/q modest recoveri
vs driven oncolog reduc opex y/i increment tax
benefit given product mix paus share buyback net effect
chang bring ep
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
idc link barclay live interact chart
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
support sale eclips driven
strong adopt across lung kidney triple-
neg breast cancer addit expect
competitior combin impact
keytruda trend across lung kidney cancer
better expect keytruda perform coupl
clinic win across pipelin
pneumococc vaccin gefapix chronic cough
islatravir prep
slow keytruda trend ou region
coupl competit data across opdivo dataset
lung kidney cancer
respect coupl lower expect
margin expans
chang model
base result compani commentari outlook adjust
estim reflect larger step-down q/q modest recoveri
vs driven oncolog revenu guid reduc opex spend
y/i guid low single-digit decreas weight increment tax benefit due
product mix guid paus share buyback net effect
chang bring ep
mn except per share datanewpriornewpriornewpriortot gross total oper interest oi pre-tax incom ni attribut adjust ep s/o barclay merck co inc
carter gould herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
unless otherwis indic price sourc bloomberg reflect close price relev trade market may
last avail price time public
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur issuer
 employe non-execut director barclay plc director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past month
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic issuer
within next month
fa barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
us regul
fb barclay bank plc and/or affili benefici own long posit class equiti secur issuer
calcul accord eu regul
fc barclay bank plc and/or affili benefici own short posit class equiti secur issuer
calcul accord eu regul
fd barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
south korean regul
gd one research analyst fundament credit coverag team and/or member household long posit
common equiti secur issuer
ge one research analyst fundament equiti coverag team and/or member household long posit
common equiti secur issuer
 issuer benefici own class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement issuer provis financi servic barclay bank plc and/or
affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or relat
